Boost Your Brand Visibility with Strategic SEO, Guest Posting & Digital PR Services
In today's fast-paced digital world, ranking high on search engines isn't optional—it's essential. Whether you run a blog, an online business, a SaaS startup, or an eCommerce brand, your online presence is your biggest asset. That's where I come in.
As a professional SEO Expert, Link Building Strategist, Guest Posting & Media Outreach Specialist, I offer a complete off-page SEO package designed to get you seen, trusted, and clicked. High-Authority Guest Posting Secure placements on top-tier websites (DA 50+)
Niche-relevant blogs across multiple industries
Do-follow backlinks that boost your authority and rankings
SEO-optimized, original content written by experts White-hat backlinks only
Contextual link insertions
Manual outreach campaigns
Competitor backlink analysis and reverse engineering Digital PR & Media Outreach Press release writing and distribution
Guaranteed placements on Google News-approved sites (e.g., APNews, DigitalJournal, Yahoo Finance)
Brand mentions and reputation building in credible publications Content Writing & Optimization SEO-optimized blog posts and landing pages
Keyword research and content planning
Engaging and conversion-driven writing for all formats Link-building campaigns tailored for SaaS
Thought leadership placements in tech and startup publications
Scalable content strategies to drive organic signups Complete Off-Page SEO Packages Backlink audits
Anchor text optimization
Monthly reporting with ranking and traffic progress Build domain authority through guest posts.
Grow organic traffic with high-quality backlinks.
Become a trusted voice in your niche through PR exposure. Dominate search results with consistent link-building.
Increase brand credibility and referral traffic.
Boost lead generation through visibility in relevant publications. Get featured on tech news and startup blogs.
Improve keyword rankings with powerful backlinks.
Gain investor and customer trust with digital PR. Rank your product pages higher on Google.
Get featured in product roundups and reviews.
Drive traffic and sales with SEO-focused strategies. 100% Manual Outreach – No spammy links or automation.
Proven Track Record – Results-driven strategies with testimonials.
Customized Campaigns – Tailored to your industry and audience.
End-to-End Service – From ideation to placement, I handle it all.
Whether you're just getting started or scaling up, strategic off-page SEO and PR is the missing piece to long-term digital success. Let's build your brand the smart way—with powerful backlinks, quality placements, and high-converting content.
📩 Get in touch now and request a customized backlink plan or guest post package for your niche.
Email
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
S&P 500 closes just shy of a record high
The S&P 500 (^GSPC) closed about 3 points short of a new record high on Thursday. The Nasdaq Composite (^IXIC) and Dow Jones Industrial Average (^DJI) both posted gains as well. Stocks got a boost from calming geopolitical tensions, and White House press secretary Karoline Leavitt saying that July 9 "is not critical" for countries to reach new trade deals with the US. Yahoo Finance Reporters Julie Hyman and Josh Schafer recap the action at the close. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. That closing bell on Wall Street and now it's market domination overtime, giving you the full team coverage of all the moves, gets you up to speed on the action from today's trade. Yahoo finances Julie Hyman, as well as Christine Short, head of research at Wall Street Horizon and TMX company, and Yahoo finances Joshfer here to break down the moves today. Let's get it down to Julie Hyman, the New York Stock Exchange for more where we closed. Julie. Well, I keep refreshing my numbers, but it looks like we closed just a hair shy about three point shy of that all-time record for the S&P 500. Didn't quite get it there. Also looks like we are just shy of that level on the Nasdaq composite. As a reminder, the numbers to watch there, 614415 on the S&P 500, the Nasdaq composite 20,173. So on both of those counts, a little short. The Nasdaq 100 though, there's your consolation prize. Uh, it closed a record for the second straight day. The S&P finishing higher still by about 8/10 of 1%, the Dow 9/10, the Nasdaq closer to 1% here. Um, and a lot of what is going on here is simple momentum, right? We're getting close to the end of the quarter. You see a lot of folks who want to book gains for the quarter and they're piling into this rally that we've seen in the market. And then there is also sort of the changing perspective on what we might see from the Federal Reserve. Maybe some ramping up of bets that we could get a cut in July or at the very least we'll get a couple of cuts before the end of the year. That seems to be driving some of the momentum as well. Josh, what are you seeing today? Hey Julie, yeah, I'm going to take a look at the sector action to start us off here. So we did see a pretty broad rally. So we didn't get our record that we were all hoping for and getting excited for, for something to sort of hang our hats on. But when I look at this sector action, it was pretty positive overall, I would say. I mean, you're starting to see broader participation in this rally. That was a key theme we were talking about yesterday for a little while. It was just XLK and tech that was leading this market over the last 10 days. But you look here, you're seeing utilities, consumer discretionary, all the way down to energy, which led today. So you're seeing broader participation in this rally. There was some positive action at two in the Magnificent 7. You saw Amazon up over 2%. Meta also up over 2%. And Julie just mentioned momentum, which is something we've been talking a lot about, that factor where a winning stock sort of keeps continuing to win. One stock that that's certainly been happening that was up over 7% today is Circle. This stock has absolutely soared since its IPO. Stock is up over 500%. But that's sort of where the market continues to be and where a lot of the exciting action continues to be in this market has been in names like a circle where those winners just keep on winning, Josh. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
5 hours ago
- Business Wire
Law Offices of Howard G. Smith Encourages Hims & Hers Health, Inc. (HIMS) Investors To Inquire About Securities Fraud Class Action
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Hims & Hers Health, Inc. ('Hims' or the 'Company') (NYSE: HIMS) securities between April 29, 2025 and June 22, 2025, inclusive (the 'Class Period'). Hims investors have until August 25, 2025 to file a lead plaintiff motion. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN HIMS & HERS HEALTH, INC. (HIMS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of 'a bundled offering of Novo Nordisk's FDA-approved Wegovy on the Hims & Hers platform.' On June 23, 2025, before the market opened, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims, 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' The press release stated that Hims 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization.'' The press release further stated '[b]ased on Novo Nordisk's investigation, the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China' which 'FDA has never authorized or approved' and which may contain 'unsafe and illicit foreign ingredients.' On this news, the Company's share price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, on unusually heavy trading volume. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Contact Us To Participate or Learn More: If you purchased Hims securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
7 hours ago
- Business Wire
Law Offices of Frank R. Cruz Encourages Hims & Hers Health, Inc. (HIMS) Investors To Inquire About Securities Fraud Class Action
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Hims & Hers Health, Inc. ('Hims' or the 'Company') (NYSE: HIMS) securities between , inclusive (the 'Class Period'). Hims investors have until August 25, 2025 to file a lead plaintiff motion. Law Offices of Frank R. Cruz Encourages Hims & Hers Health, Inc. (HIMS) Investors To Inquire About Securities Fraud Class Action Share IF YOU SUFFERED A LOSS ON YOUR HIMS & HERS HEALTH, INC. (HIMS) INVESTMENTS, CLICK HERE TO SUBMIT A CLAIM TO POTENTIALLY RECOVER YOUR LOSSES IN THE ONGOING SECURITIES FRAUD LAWSUIT. You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at info@ by telephone at (310) 914-5007, or visit our website at What Happened? On April 29, 2025, Hims announced a long-term collaboration with Novo Nordisk, starting with the immediate sale of 'a bundled offering of Novo Nordisk's FDA-approved Wegovy on the Hims & Hers platform.' On June 23, 2025, before the market opened, Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims, 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' The press release stated that Hims 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization.'' The press release further stated '[b]ased on Novo Nordisk's investigation, the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China' which 'FDA has never authorized or approved' and which may contain 'unsafe and illicit foreign ingredients.' On this news, the Company's share price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, on unusually heavy trading volume. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Contact Us To Participate or Learn More: If you purchased Hims securities, wish to learn more about this action, or have any questions concerning this announcement or your rights or interests with respect to these matters, please click HERE or contact us at: Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Telephone: 310-914-5007 Email: info@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
